| __timestamp | Intra-Cellular Therapies, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 7751000 |
| Thursday, January 1, 2015 | 18187286 | 10251000 |
| Friday, January 1, 2016 | 24758063 | 9575000 |
| Sunday, January 1, 2017 | 23666957 | 10912000 |
| Monday, January 1, 2018 | 30099855 | 11049000 |
| Tuesday, January 1, 2019 | 64947625 | 11646000 |
| Wednesday, January 1, 2020 | 186363444 | 13265000 |
| Friday, January 1, 2021 | 272611040 | 25805000 |
| Saturday, January 1, 2022 | 358782000 | 35182000 |
| Sunday, January 1, 2023 | 409864000 | 94999000 |
Unlocking the unknown
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Viridian Therapeutics, Inc. over the past decade. Since 2014, Intra-Cellular Therapies has seen a staggering increase in SG&A expenses, growing nearly 40 times by 2023. In contrast, Viridian Therapeutics experienced a more modest growth, with expenses increasing by approximately 12 times during the same period.
The data reveals that Intra-Cellular Therapies' expenses surged significantly in 2020, coinciding with the global pandemic, while Viridian's expenses remained relatively stable until a notable rise in 2023. This divergence highlights differing strategic approaches in managing operational costs. Understanding these trends provides valuable insights into the financial strategies of these biotech firms, offering a glimpse into their operational priorities and market positioning.
Breaking Down SG&A Expenses: AbbVie Inc. vs Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Viridian Therapeutics, Inc.
Takeda Pharmaceutical Company Limited vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs BioMarin Pharmaceutical Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Viridian Therapeutics, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Viridian Therapeutics, Inc.
Ascendis Pharma A/S vs Viridian Therapeutics, Inc.: SG&A Expense Trends
Pharming Group N.V. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Lantheus Holdings, Inc. vs Viridian Therapeutics, Inc.
Comparing SG&A Expenses: TG Therapeutics, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Viking Therapeutics, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Galapagos NV vs Viridian Therapeutics, Inc.